prazosin has been researched along with Hypertension, Pulmonary in 15 studies
Prazosin: A selective adrenergic alpha-1 antagonist used in the treatment of HEART FAILURE; HYPERTENSION; PHEOCHROMOCYTOMA; RAYNAUD DISEASE; PROSTATIC HYPERTROPHY; and URINARY RETENTION.
prazosin : A member of the class of piperazines that is piperazine substituted by a furan-2-ylcarbonyl group and a 4-amino-6,7-dimethoxyquinazolin-2-yl group at positions 1 and 4 respectively.
Hypertension, Pulmonary: Increased VASCULAR RESISTANCE in the PULMONARY CIRCULATION, usually secondary to HEART DISEASES or LUNG DISEASES.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A 51-year-old patient with COPD, obesity, and pulmonary hypertension underwent long-term prazosin therapy after a successful hemodynamic response to 1 mg of oral prazosin." | 7.68 | Long-term prazosin therapy for COPD pulmonary hypertension. ( Lewczuk, J; Piszko, P; Sobkowicz-Woźniak, B; Spikowski, J; Wrabec, K, 1992) |
| "The effect of vasodilator therapy in chronic obstructive lung disease with pulmonary hypertension was evaluated in eight patients during oral prazosin therapy (2-10 mg day-1)." | 7.67 | Improved haemodynamics but reduced arterial blood oxygenation, at rest and during exercise after long-term oral prazosin therapy in chronic cor pulmonale. ( Halvorsen, FJ; Jentoft, H; Vik-Mo, H; Walde, N, 1985) |
| "Prazosin was studied in 11 patients (10 men, 1 women) aged 63 +/- 7 years with advanced c." | 6.67 | [Clinical and hemodynamic evaluation of 6-week treatment of pulmonary hypertension in chronic obstructive lung diseases (COLD) with low dose of prazosin]. ( Lewczuk, J; Palka, PS; Piszko, P; Porada, A; Sobkowicz-Woźniak, B; Spikowski, J; Szczygielski, J; Trzesicka, M; Wrabec, K, 1990) |
| " During 12 weeks of prednisone treatment in a dosage of 40 mg daily, her condition markedly deteriorated clinically and hemodynamically as manifested by pulmonary artery pressure (PAP), pulmonary vascular resistance (PVR), cardiac output (CO), mixed venous O2 saturation, and systemic vascular resistance (SVR)." | 5.28 | Nifedipine and prazosin in the management of pulmonary hypertension in CREST syndrome. ( Dresner-Feigin, R; Galun, E; Glikson, M; Pollack, A; Rubinow, A, 1990) |
| "A single dose of capoten (25 mg) and prazosin (I mg) was given to 82 patients with stable pulmonary hypertension and chronic non-specific pulmonary diseases and to 34 patients with the above condition and arterial hypertension." | 5.06 | [Pharmacologic effects of peripheral vasodilators in patients with secondary pulmonary hypertension]. ( Abrosimov, AG; Belov, AM; Kukes, VG; Nasyrov, ShN; Tsoĭ, AN, 1989) |
| "The effect of monocrotaline-induced pulmonary hypertension on alpha(1)-adrenoceptor-mediated contractions of pulmonary artery segments was studied." | 3.72 | Alpha 1-adrenoceptor subtypes mediating noradrenaline-induced contraction of pulmonary artery from pulmonary hypertensive rats. ( Chandrasekhar, B; Kadavil, EA; Oriowo, MA, 2003) |
| "A 51-year-old patient with COPD, obesity, and pulmonary hypertension underwent long-term prazosin therapy after a successful hemodynamic response to 1 mg of oral prazosin." | 3.68 | Long-term prazosin therapy for COPD pulmonary hypertension. ( Lewczuk, J; Piszko, P; Sobkowicz-Woźniak, B; Spikowski, J; Wrabec, K, 1992) |
| "The effect of vasodilator therapy in chronic obstructive lung disease with pulmonary hypertension was evaluated in eight patients during oral prazosin therapy (2-10 mg day-1)." | 3.67 | Improved haemodynamics but reduced arterial blood oxygenation, at rest and during exercise after long-term oral prazosin therapy in chronic cor pulmonale. ( Halvorsen, FJ; Jentoft, H; Vik-Mo, H; Walde, N, 1985) |
| "Prazosin was studied in 11 patients (10 men, 1 women) aged 63 +/- 7 years with advanced c." | 2.67 | [Clinical and hemodynamic evaluation of 6-week treatment of pulmonary hypertension in chronic obstructive lung diseases (COLD) with low dose of prazosin]. ( Lewczuk, J; Palka, PS; Piszko, P; Porada, A; Sobkowicz-Woźniak, B; Spikowski, J; Szczygielski, J; Trzesicka, M; Wrabec, K, 1990) |
| " During 12 weeks of prednisone treatment in a dosage of 40 mg daily, her condition markedly deteriorated clinically and hemodynamically as manifested by pulmonary artery pressure (PAP), pulmonary vascular resistance (PVR), cardiac output (CO), mixed venous O2 saturation, and systemic vascular resistance (SVR)." | 1.28 | Nifedipine and prazosin in the management of pulmonary hypertension in CREST syndrome. ( Dresner-Feigin, R; Galun, E; Glikson, M; Pollack, A; Rubinow, A, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (66.67) | 18.7374 |
| 1990's | 4 (26.67) | 18.2507 |
| 2000's | 1 (6.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Oriowo, MA | 1 |
| Chandrasekhar, B | 1 |
| Kadavil, EA | 1 |
| Coma-Canella, I | 1 |
| Lopez-Sendon, J | 1 |
| Kanemoto, N | 3 |
| Imaoka, C | 2 |
| Goto, Y | 3 |
| Hayashi, Y | 1 |
| Ubukata, S | 1 |
| Hojo, Y | 1 |
| Elkayam, U | 1 |
| Lewczuk, J | 3 |
| Sobkowicz-Woźniak, B | 2 |
| Piszko, P | 2 |
| Spikowski, J | 2 |
| Wrabec, K | 3 |
| Porada, A | 1 |
| Trzesicka, M | 1 |
| Palka, PS | 1 |
| Szczygielski, J | 1 |
| Glikson, M | 1 |
| Pollack, A | 1 |
| Dresner-Feigin, R | 1 |
| Galun, E | 1 |
| Rubinow, A | 1 |
| Yamaguchi, H | 1 |
| Shiina, Y | 1 |
| Kukes, VG | 1 |
| Tsoĭ, AN | 1 |
| Abrosimov, AG | 1 |
| Nasyrov, ShN | 1 |
| Belov, AM | 1 |
| Powers, K | 1 |
| Fyfe, DA | 1 |
| Taylor, AB | 1 |
| Halushka, PV | 1 |
| Crawford, FA | 1 |
| Funayama, N | 1 |
| Takenaka, T | 1 |
| Horimoto, M | 1 |
| Igarashi, T | 1 |
| Neild, TO | 1 |
| McLean, JR | 1 |
| Mee, RB | 1 |
| Vik-Mo, H | 1 |
| Walde, N | 1 |
| Jentoft, H | 1 |
| Halvorsen, FJ | 1 |
1 review available for prazosin and Hypertension, Pulmonary
| Article | Year |
|---|---|
[Value of vasodilator agents in the treatment of diseases with pulmonary hypertension caused by chronic obstructive lung diseases].
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Calcium Channel B | 1991 |
2 trials available for prazosin and Hypertension, Pulmonary
| Article | Year |
|---|---|
[Clinical and hemodynamic evaluation of 6-week treatment of pulmonary hypertension in chronic obstructive lung diseases (COLD) with low dose of prazosin].
Topics: Administration, Oral; Aged; Hemodynamics; Humans; Hypertension, Pulmonary; Lung Diseases, Obstructiv | 1990 |
[Pharmacologic effects of peripheral vasodilators in patients with secondary pulmonary hypertension].
Topics: Adolescent; Adult; Aged; Captopril; Clinical Trials as Topic; Hemodynamics; Humans; Hypertension, Pu | 1989 |
12 other studies available for prazosin and Hypertension, Pulmonary
| Article | Year |
|---|---|
Alpha 1-adrenoceptor subtypes mediating noradrenaline-induced contraction of pulmonary artery from pulmonary hypertensive rats.
Topics: Adrenergic alpha-1 Receptor Agonists; Adrenergic alpha-1 Receptor Antagonists; Animals; Dose-Respons | 2003 |
Haemodynamic effects of nifedipine, nitroglycerine and prazosin in pulmonary hypertension following ingestion of toxic oil.
Topics: Adolescent; Adult; Child; Female; Hemodynamics; Humans; Hypertension, Pulmonary; Male; Middle Aged; | 1983 |
A case of primary pulmonary hypertension treated with prazosin and isosorbide dinitrate.
Topics: Administration, Oral; Adult; Drug Therapy, Combination; Electrocardiography; Female; Humans; Hyperte | 1984 |
[Primary pulmonary hypertension in a brother and a sister--combined administration of prazosin and isosorbide dinitrate].
Topics: Adult; Drug Combinations; Female; Humans; Hypertension, Pulmonary; Isosorbide Dinitrate; Male; Prazo | 1983 |
Vasodilator therapy in primary pulmonary hypertension.
Topics: Adult; Diazoxide; Female; Hemodynamics; Humans; Hydralazine; Hypertension, Pulmonary; Isoproterenol; | 1981 |
Long-term prazosin therapy for COPD pulmonary hypertension.
Topics: Humans; Hypertension, Pulmonary; Lung Diseases, Obstructive; Male; Middle Aged; Obesity; Prazosin; R | 1992 |
Nifedipine and prazosin in the management of pulmonary hypertension in CREST syndrome.
Topics: Adult; Drug Therapy, Combination; Esophageal Motility Disorders; Hemodynamics; Humans; Hypertension, | 1990 |
Reversibility of primary pulmonary hypertension with vasodilator, anticoagulant and nocturnal oxygen therapy.
Topics: Adolescent; Combined Modality Therapy; Drug Therapy, Combination; Female; Humans; Hypertension, Pulm | 1989 |
Treatment of pulmonary vasospasm with prazosin after atrial septal defect closure in a child.
Topics: Heart Septal Defects; Humans; Hypertension, Pulmonary; Infant; Male; Postoperative Period; Prazosin | 1989 |
[A case of primary pulmonary hypertension--acute and chronic effect of vasodilators].
Topics: Adult; Drug Therapy, Combination; Female; Humans; Hypertension, Pulmonary; Isosorbide Dinitrate; Pra | 1987 |
An in vitro study of the pharmacological and electrophysiological properties and the adrenergic innervation of small pulmonary arteries from children with pulmonary hypertension.
Topics: Acetylcholine; Catecholamines; Child; Child, Preschool; Dose-Response Relationship, Drug; Electric S | 1986 |
Improved haemodynamics but reduced arterial blood oxygenation, at rest and during exercise after long-term oral prazosin therapy in chronic cor pulmonale.
Topics: Administration, Oral; Aged; Carbon Dioxide; Chronic Disease; Female; Hemodynamics; Humans; Hypertens | 1985 |